Wells Fargo Reiterates Overweight Rating on Nurix (NRIX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/7/2026
- Equities poised for best week since April as payrolls surprise eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Oil gains on pending Iran-Oman deal over Hormuz
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Citi says buy the pullback in memory stocks as upcycle is still in early innings
- Stocks close lower as investors eye Mideast talks, earnings
- The Trade Desk Inc. (TTD) Tops Q2 EPS by 16c, Misses on Revenue; Offers Weak Q3 Revenue Guidance
- Apollo to acquire easyJet for £5.7B in cash deal
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
October 11, 2024 4:00 PM EDTInitiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia patient population with Fast Track Designation from the FDA
Initiated Phase 1b dose expansion of NX-5948 in Waldenstroms macroglobulinemia, follicular lymphoma and marginal zone lymphoma patients
Reinitiated enrollment for NX-2127 in a Phase 1a/b trial in oncology
Presented preclinical data on Degrader-Antibody Conjugates (DACs), a new class of therapeutics
Well capitalized with cash and marketable securities of $457.5 million
SAN FRANCISCO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Nurix... More
